The clinical and prognostic significance of CMTM6/PD-L1 in oncology
The recent discovery of CMTM6 and to a lesser extent CMTM4, two members of the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family, as master positive regulators of PD-L1 expression, the primary ligand of programmed cell death 1 (PD-1), on tumor and immune cells has opene...
Saved in:
| Published in | Clinical & translational oncology Vol. 24; no. 8; pp. 1478 - 1491 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Cham
Springer International Publishing
01.08.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The recent discovery of CMTM6 and to a lesser extent CMTM4, two members of the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family, as master positive regulators of PD-L1 expression, the primary ligand of programmed cell death 1 (PD-1), on tumor and immune cells has opened new horizons for investigating the role of CMTM6/CMTM4 in different aspects of oncology including their clinical and prognostic values in different cancer types. The absence of a specific review article addressing the available results about the clinical and prognostic roles of CMTM6 alone and/or in combination with PD-L1 in cancer has encouraged us to write this paper. |
|---|---|
| AbstractList | The recent discovery of CMTM6 and to a lesser extent CMTM4, two members of the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family, as master positive regulators of PD-L1 expression, the primary ligand of programmed cell death 1 (PD-1), on tumor and immune cells has opened new horizons for investigating the role of CMTM6/CMTM4 in different aspects of oncology including their clinical and prognostic values in different cancer types. The absence of a specific review article addressing the available results about the clinical and prognostic roles of CMTM6 alone and/or in combination with PD-L1 in cancer has encouraged us to write this paper. |
| Author | Yaseen, Mahmoud Mohammad Abuharfeil, Nizar Mohammad Darmani, Homa |
| Author_xml | – sequence: 1 givenname: Mahmoud Mohammad orcidid: 0000-0001-8944-9151 surname: Yaseen fullname: Yaseen, Mahmoud Mohammad email: mmyasin08@xams.just.edu.jo, mahmoudhiv1@yahoo.com organization: Department of Biotechnology and Genetic Engineering, Faculty of Science and Arts, Jordan University of Science and Technology – sequence: 2 givenname: Nizar Mohammad surname: Abuharfeil fullname: Abuharfeil, Nizar Mohammad organization: Department of Biotechnology and Genetic Engineering, Faculty of Science and Arts, Jordan University of Science and Technology – sequence: 3 givenname: Homa surname: Darmani fullname: Darmani, Homa organization: Department of Biotechnology and Genetic Engineering, Faculty of Science and Arts, Jordan University of Science and Technology |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35278198$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kD1PwzAQhi0Eoh_wBxiQR5ZQXxzb8YjKp9QKhjJbjuOEVKld4mbov8clBTExnO6k971Xd88EnTrvLEJXQG6BEDELkBKZJSRNY-UACTlBY-BSJpQwdvpnHqFJCGsSJw5wjkaUpSIHmY_RfPVhsWkb1xjdYu1KvO187XzYNQaHpnZNFRVnLPYVni9XSz57u08WgBuHvTO-9fX-Ap1Vug328tin6P3xYTV_ThavTy_zu0ViaCZ2CbVaak6E5TnQKgMhqpJVWkpWcl3oVIsCUmapFjwvhCgBclNKZjWn1Ggq6RTdDLnxxM_ehp3aNMHYttXO-j6olNNcZDmwgzUdrKbzIXS2Utuu2ehur4CoAzw1wFMRnvqGp0hcuj7m98XGlr8rP7SigQ6GECVX206tfd-5-PN_sV_ibnoY |
| CitedBy_id | crossref_primary_10_1097_MD_0000000000036480 |
| Cites_doi | 10.1080/2162402X.2019.1629261 10.1016/j.jhep.2017.05.014 10.1158/0008-5472.can-03-3259 10.3892/or.2019.7244 10.1016/j.intimp.2020.106478 10.1056/NEJMoa1603702 10.1016/j.jtho.2019.09.014 10.1016/j.ejca.2013.02.015 10.1021/acsmedchemlett.9b00423 10.1056/NEJMoa1606774 10.3892/ol.2021.12516 10.1002/hep.29762 10.1158/0008-5472.CAN-09-3690 10.1158/2326-6066.CIR-15-0296 10.1098/rsob.200111 10.1038/nature23669 10.1158/2326-6066.CIR-14-0215 10.1111/cas.13072 10.1007/s00262-020-02741-2 10.1007/s12094-013-1114-1 10.1038/nature13904 10.1158/1078-0432.CCR-06-3045 10.1056/NEJMoa1504627 10.1038/nature25015 10.1186/s12943-018-0864-3 10.3389/fonc.2020.588530 10.21037/atm.2017.11.26 10.1038/nature04444 10.1016/j.bbrep.2019.100690 10.1016/s0140-6736(12)61728-0 10.21037/atm-20-7616 10.1016/j.intimp.2020.106864 10.18632/oncotarget.11685 10.1038/nature23643 10.1002/jcb.28607 10.1016/j.jhep.2020.01.007 10.1159/000509033 10.7717/peerj.9536 10.1056/NEJMoa1411087 10.1038/nature13954 10.1136/jitc-2020-001638 10.1016/j.molonc.2015.05.009 10.2147/OTT.S105862 10.1158/0008-5472.CAN-17-2445 10.1089/dna.2018.4274 10.4997/JRCPE.2020.409 10.3389/fonc.2020.585961 10.1056/NEJMoa1200694 10.18632/oncotarget.5463 10.1158/1535-7163.MCT-14-0983 10.1371/journal.pone.0182692 10.1007/s00262-020-02691-9 10.1016/s0140-6736(17)31046-2 10.1001/jamanetworkopen.2019.2535 10.1007/s11684-020-0797-2 10.1093/intimm/dxaa018 10.1007/s00262-021-02931-6 10.1158/2326-6066.CIR-19-0394 10.1371/journal.pone.0088557 10.1002/eji.201041235 10.1016/j.hoc.2015.07.003 10.1158/1078-0432.CCR-16-0066 10.1016/j.oooo.2021.02.019 10.1007/s00432-021-03616-4 10.1016/j.intimp.2019.105999 10.2147/OTT.S149786 10.1186/s40425-016-0163-8 10.1002/ijc.29210 10.1007/s00432-019-02942-y 10.1002/hep4.1682 10.1007/s10120-021-01176-7 10.1159/000488035 10.1056/NEJMoa1510665 10.1007/s12094-018-1975-4 10.7150/ijms.46809 10.1056/NEJMoa1500596 10.4143/crt.2019.183 10.1158/1078-0432.CCR-08-1608 10.7150/thno.58390 10.1007/s11864-019-0682-x 10.1172/jci.insight.130867 10.1056/NEJMoa1507643 10.1111/odi.13766 10.1038/nm863 10.1158/2326-6066.CIR-13-0127 10.1016/j.molcel.2019.04.005 10.1038/s41388-021-01689-6 10.1038/s41388-021-01811-8 10.1080/2162402X.2020.1864909 10.3389/fimmu.2019.00168 10.1186/s12935-020-01734-6 10.1002/hep4.1643 10.1186/s12885-019-5345-6 10.1136/gutjnl-2016-311421 10.1007/s10549-019-05371-0 10.3390/cancers13051165 10.1089/dna.2018.4513 10.1186/s12943-016-0539-x 10.1056/NEJMoa1200690 10.1056/NEJMoa1501824 10.1016/j.ebiom.2018.08.012 10.3389/fimmu.2021.673912 10.1016/s0140-6736(16)32517-x 10.1007/s00262-022-03171-y |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO) 2022 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO). |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO) 2022 – notice: 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO). |
| DBID | NPM AAYXX CITATION 7X8 |
| DOI | 10.1007/s12094-022-02811-0 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1699-3055 |
| EndPage | 1491 |
| ExternalDocumentID | 10_1007_s12094_022_02811_0 35278198 |
| Genre | Journal Article Review |
| GroupedDBID | -05 -0E -5E -5G -BR -EM -SE -S~ -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 1N0 203 29B 29~ 2B. 2C~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2~H 30V 4.4 406 408 40D 40E 53G 5GY 5VR 5VS 67Z 6NX 8TC 8UJ 92F 92I 92M 93N 93R 95- 95. 95~ 96X 9D9 9DE AAAVM AABHQ AAFGU AAHNG AAIAL AAJKR AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABDZT ABECU ABFGW ABFTV ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKZE ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABWNU ABXPI ACBMV ACBRV ACBYP ACGFS ACHSB ACHVE ACHXU ACIGE ACILI ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACTTH ACVWB ACWMK ADHIR ADINQ ADJJI ADKNI ADKPE ADMDM ADOXG ADPDF ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFLOW AFNRJ AFQWF AFUIB AFWTZ AFZKB AGAYW AGDGC AGGBP AGJBK AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARMRJ AXYYD B-. BA0 BDATZ BGNMA CAG CAJEE CAJUS CCEZO CHBEP CIEJG COF CS3 CSCUP DDRTE DNIVK DPUIP EBLON EBS EIOEI EJD EN4 ESBYG F5P FA0 FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 HF~ HG5 HG6 HMJXF HRMNR HZ~ IJ- IKXTQ IMOTQ IWAJR IXD IZQ I~X I~Z J-C J0Z JBSCW JUIAU JZLTJ KOV KPH LLZTM M4Y MA- NPVJJ NQJWS NU0 O9- O93 O9I O9J OAM OVD OVEED P2P P9S PF0 PT4 Q-- Q-4 QOR QOS R-E R89 R9I ROL RPX RSV RT5 S16 S1Z S27 S37 S3B SAP SDH SHX SISQX SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 SZN T13 T8U TCJ TEORI TGQ TSG TSK TSV TT1 TUC U1F U1G U2A U5E U5O U9L UG4 UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W48 WFFXF WK8 YLTOR Z45 Z7D Z7U Z7W Z82 Z83 Z87 ZMTXR ZOVNA ~A9 ~N8 AACDK AAJBT AASML AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU NPM SJYHP AAYXX CITATION H13 7X8 |
| ID | FETCH-LOGICAL-c347t-3ea9a607e6813f4177fd5fa995d6aba2a7b125e3a768b77d118cd95ea633ca393 |
| IEDL.DBID | AGYKE |
| ISSN | 1699-3055 |
| IngestDate | Fri Oct 25 22:55:45 EDT 2024 Thu Sep 12 18:04:16 EDT 2024 Wed Oct 16 00:42:15 EDT 2024 Sat Dec 16 12:10:09 EST 2023 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Prognostic value Tumor-infiltrating immune cells Overall survival Bioinformatics Gene databases |
| Language | English |
| License | 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c347t-3ea9a607e6813f4177fd5fa995d6aba2a7b125e3a768b77d118cd95ea633ca393 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ORCID | 0000-0001-8944-9151 |
| PMID | 35278198 |
| PQID | 2638748159 |
| PQPubID | 23479 |
| PageCount | 14 |
| ParticipantIDs | proquest_miscellaneous_2638748159 crossref_primary_10_1007_s12094_022_02811_0 pubmed_primary_35278198 springer_journals_10_1007_s12094_022_02811_0 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-08-01 |
| PublicationDateYYYYMMDD | 2022-08-01 |
| PublicationDate_xml | – month: 08 year: 2022 text: 2022-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: Italy |
| PublicationTitle | Clinical & translational oncology |
| PublicationTitleAbbrev | Clin Transl Oncol |
| PublicationTitleAlternate | Clin Transl Oncol |
| PublicationYear | 2022 |
| Publisher | Springer International Publishing |
| Publisher_xml | – name: Springer International Publishing |
| References | Brahmer (CR12) 2012; 366 Liu, Li, Zhang, Zhang, Wei (CR42) 2021 Bei (CR78) 2017; 10 Dent (CR49) 2007; 13 Mazel (CR4) 2015; 9 CR32 Calderaro (CR81) 2017; 67 Patel, Kurzrock (CR37) 2015; 14 Borghaei (CR59) 2015; 373 Yaseen, Abuharfeil, Homa, Daoud (CR102) 2020; 10 Zugazagoitia (CR24) 2019; 14 Van Der Kraak (CR103) 2016; 4 Yaseen, Abuharfeil, Darmani, Daoud (CR53) 2020; 10 Ziol (CR82) 2018; 68 Zhao (CR106) 2020; 10 Cheng (CR56) 2018; 78 Jiang (CR85) 2015; 6 Ishihara (CR105) 2021; 147 Zhu (CR69) 2021 Sierro (CR88) 2011; 41 Burr (CR22) 2017; 549 Liu (CR80) 2021; 70 Guan (CR20) 2018; 35 Eriksen (CR99) 2019; 19 Ho (CR100) 2019; 145 Haslam, Prasad (CR21) 2019; 2 Wang (CR70) 2020; 17 Lozano (CR72) 2012; 380 Xie, Huang, Ye, Qian (CR38) 2019; 77 Powles (CR14) 2014; 515 Bonaventura (CR84) 2019; 10 Motzer (CR17) 2015; 373 Liu, Sun (CR83) 2021; 11 Gao (CR75) 2009; 15 Wang (CR44) 2021; 21 Yamamoto (CR45) 2020; 32 Zhang, Zhao, Wang (CR92) 2021; 21 Jin (CR8) 2021 Tanaka (CR40) 2019; 42 Chen (CR67) 2020; 8 Soliman, Khalil, Antonia (CR5) 2014; 9 Tumeh (CR90) 2014; 515 Le (CR16) 2015; 372 Rittmeyer (CR61) 2017; 389 Yi (CR35) 2018; 17 Zhou (CR73) 2018; 7 Chui (CR31) 2022; 6 Peng (CR95) 2021 Ansell (CR13) 2015; 372 Li (CR55) 2019 Huang, Ran, Shao, Li (CR34) 2019; 178 Puram, Rocco (CR66) 2015; 29 Brahmer (CR60) 2015; 373 Mittendorf (CR3) 2014; 2 Winograd (CR89) 2015; 3 Gao (CR25) 2019; 20 Zhang (CR7) 2018; 553 Yaseen, Abuharfeil, Darmani, Daoud (CR52) 2020 Tian (CR48) 2021; 9 Barber (CR6) 2006; 439 Wu (CR30) 2021 Li (CR97) 2016; 15 Talari, Goyal (CR93) 2020; 50 Birnbaum (CR46) 2016; 7 Nghiem (CR18) 2016; 374 Koh, Han, Haam, Jung, Lee (CR58) 2019; 8 Goydel, Rader (CR10) 2021; 40 Curiel (CR87) 2003; 9 Pang (CR29) 2021; 70 Mocan, Sparchez, Craciun, Bora, Leucuta (CR39) 2019; 21 Papatheodoridis (CR74) 2020; 72 Garon (CR15) 2015; 372 El-Khoueiry (CR76) 2017; 389 Blank (CR86) 2004; 64 Tu (CR9) 2019; 74 Gu (CR36) 2017; 12 Xiao (CR43) 2021 Ishibashi (CR1) 2016; 4 Reck (CR62) 2016; 375 Wu (CR71) 2020; 10 Li, Chen, Gu, Sun, Li (CR27) 2020; 8 Droeser (CR96) 2013; 49 Vincent (CR101) 2010; 70 Wang, Teng, Kong, Yu (CR33) 2016; 9 Bei, Tan, Zhu, Wang, Tan (CR79) 2018; 37 Zhu (CR77) 2019; 38 Mezzadra (CR23) 2017; 549 Shang (CR63) 2020; 88 Jin (CR41) 2020; 52 Ubukata (CR91) 2021; 99 Topalian (CR11) 2012; 366 Braun, Burke, Van Allen (CR19) 2016; 22 Zhao (CR57) 2019; 120 Ganau (CR51) 2014; 16 Fu (CR104) 2020; 10 Zeisbrich (CR28) 2021; 12 Zhang (CR2) 2016; 107 Lyons (CR50) 2019; 20 Martinez-Morilla, Zugazagoitia, Wong, Kluger, Rimm (CR94) 2020; 10 Yugawa (CR26) 2021; 5 Kargbo (CR54) 2019; 10 Ferlay (CR65) 2015; 136 Mamessier, Birnbaum, Finetti, Birnbaum, Bertucci (CR47) 2018; 6 Zhang (CR68) 2021 Wang (CR64) 2020; 83 Masugi (CR98) 2017; 66 MH Jin (2811_CR41) 2020; 52 SP Patel (2811_CR37) 2015; 14 Q Gao (2811_CR75) 2009; 15 J Zhang (2811_CR7) 2018; 553 P Bonaventura (2811_CR84) 2019; 10 S Zhang (2811_CR68) 2021 C Zhang (2811_CR92) 2021; 21 SL Topalian (2811_CR11) 2012; 366 MH Jin (2811_CR8) 2021 T Powles (2811_CR14) 2014; 515 SS Jiang (2811_CR85) 2015; 6 ML Burr (2811_CR22) 2017; 549 W Huang (2811_CR34) 2019; 178 QH Peng (2811_CR95) 2021 TJ Curiel (2811_CR87) 2003; 9 C Bei (2811_CR78) 2017; 10 NN Chui (2811_CR31) 2022; 6 TG Lyons (2811_CR50) 2019; 20 A Haslam (2811_CR21) 2019; 2 C Blank (2811_CR86) 2004; 64 T Mocan (2811_CR39) 2019; 21 X Wu (2811_CR30) 2021 MM Yaseen (2811_CR53) 2020; 10 L Chen (2811_CR67) 2020; 8 PT Nghiem (2811_CR18) 2016; 374 A Rittmeyer (2811_CR61) 2017; 389 M Ziol (2811_CR82) 2018; 68 X Shang (2811_CR63) 2020; 88 M Reck (2811_CR62) 2016; 375 R Lozano (2811_CR72) 2012; 380 J Zhou (2811_CR73) 2018; 7 J Wang (2811_CR44) 2021; 21 X Zhu (2811_CR77) 2019; 38 EB Garon (2811_CR15) 2015; 372 MM Yaseen (2811_CR52) 2020 M Ganau (2811_CR51) 2014; 16 GV Papatheodoridis (2811_CR74) 2020; 72 D Fu (2811_CR104) 2020; 10 HL Ho (2811_CR100) 2019; 145 SR Sierro (2811_CR88) 2011; 41 YW Koh (2811_CR58) 2019; 8 X Li (2811_CR27) 2020; 8 J Ferlay (2811_CR65) 2015; 136 R Dent (2811_CR49) 2007; 13 2811_CR32 X Wang (2811_CR33) 2016; 9 DL Barber (2811_CR6) 2006; 439 M Ishibashi (2811_CR1) 2016; 4 E Tanaka (2811_CR40) 2019; 42 S Martinez-Morilla (2811_CR94) 2020; 10 E Mamessier (2811_CR47) 2018; 6 J Brahmer (2811_CR60) 2015; 373 XL Wang (2811_CR70) 2020; 17 P Zhang (2811_CR2) 2016; 107 Q Li (2811_CR55) 2019 BY Cheng (2811_CR56) 2018; 78 L Van Der Kraak (2811_CR103) 2016; 4 H Wang (2811_CR64) 2020; 83 M Zeisbrich (2811_CR28) 2021; 12 H Borghaei (2811_CR59) 2015; 373 Y Tian (2811_CR48) 2021; 9 Y Yamamoto (2811_CR45) 2020; 32 DJ Birnbaum (2811_CR46) 2016; 7 M Xie (2811_CR38) 2019; 77 F Gao (2811_CR25) 2019; 20 LL Liu (2811_CR80) 2021; 70 M Yi (2811_CR35) 2018; 17 ZZ Wu (2811_CR71) 2020; 10 YT Liu (2811_CR83) 2021; 11 Y Zhao (2811_CR106) 2020; 10 AC Eriksen (2811_CR99) 2019; 19 C Bei (2811_CR79) 2018; 37 JR Brahmer (2811_CR12) 2012; 366 W Zhao (2811_CR57) 2019; 120 J Zugazagoitia (2811_CR24) 2019; 14 L Gu (2811_CR36) 2017; 12 M Mazel (2811_CR4) 2015; 9 S Ishihara (2811_CR105) 2021; 147 Y Li (2811_CR97) 2016; 15 RJ Motzer (2811_CR17) 2015; 373 PC Tumeh (2811_CR90) 2014; 515 X Pang (2811_CR29) 2021; 70 R Mezzadra (2811_CR23) 2017; 549 X Tu (2811_CR9) 2019; 74 RS Goydel (2811_CR10) 2021; 40 M Xiao (2811_CR43) 2021 SW Zhu (2811_CR69) 2021 RA Droeser (2811_CR96) 2013; 49 Y Liu (2811_CR42) 2021 Y Ubukata (2811_CR91) 2021; 99 K Yugawa (2811_CR26) 2021; 5 Y Masugi (2811_CR98) 2017; 66 R Winograd (2811_CR89) 2015; 3 MM Yaseen (2811_CR102) 2020; 10 H Soliman (2811_CR5) 2014; 9 J Calderaro (2811_CR81) 2017; 67 DT Le (2811_CR16) 2015; 372 AB El-Khoueiry (2811_CR76) 2017; 389 X Guan (2811_CR20) 2018; 35 SM Ansell (2811_CR13) 2015; 372 EA Mittendorf (2811_CR3) 2014; 2 RB Kargbo (2811_CR54) 2019; 10 J Vincent (2811_CR101) 2010; 70 DA Braun (2811_CR19) 2016; 22 SV Puram (2811_CR66) 2015; 29 K Talari (2811_CR93) 2020; 50 |
| References_xml | – volume: 8 year: 2019 ident: CR58 article-title: Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1629261 contributor: fullname: Lee – volume: 67 start-page: 727 year: 2017 end-page: 738 ident: CR81 article-title: Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification publication-title: J Hepatol doi: 10.1016/j.jhep.2017.05.014 contributor: fullname: Calderaro – volume: 64 start-page: 1140 year: 2004 end-page: 1145 ident: CR86 article-title: PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells publication-title: Cancer Res doi: 10.1158/0008-5472.can-03-3259 contributor: fullname: Blank – volume: 42 start-page: 1459 year: 2019 end-page: 1466 ident: CR40 article-title: Expression of circular RNA CDR1AS in colon cancer cells increases cell surface PDL1 protein levels publication-title: Oncol Rep doi: 10.3892/or.2019.7244 contributor: fullname: Tanaka – volume: 83 year: 2020 ident: CR64 article-title: Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2020.106478 contributor: fullname: Wang – volume: 374 start-page: 2542 year: 2016 end-page: 2552 ident: CR18 article-title: PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1603702 contributor: fullname: Nghiem – volume: 14 start-page: 2084 year: 2019 end-page: 2096 ident: CR24 article-title: Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small cell lung cancer publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2019.09.014 contributor: fullname: Zugazagoitia – volume: 49 start-page: 2233 year: 2013 end-page: 2242 ident: CR96 article-title: Clinical impact of programmed cell death ligand 1 expression in colorectal cancer publication-title: Eur J Cancer doi: 10.1016/j.ejca.2013.02.015 contributor: fullname: Droeser – volume: 10 start-page: 1370 year: 2019 end-page: 1371 ident: CR54 article-title: PROTAC Degradation of IRAK4 for the treatment of Cancer publication-title: ACS Med Chem Lett doi: 10.1021/acsmedchemlett.9b00423 contributor: fullname: Kargbo – volume: 375 start-page: 1823 year: 2016 end-page: 1833 ident: CR62 article-title: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1606774 contributor: fullname: Reck – volume: 21 start-page: 254 year: 2021 ident: CR44 article-title: Interleukin-1 receptor-associated kinase 4 as a potential biomarker: overexpression predicts poor prognosis in patients with glioma publication-title: Oncol Lett doi: 10.3892/ol.2021.12516 contributor: fullname: Wang – volume: 68 start-page: 103 year: 2018 end-page: 112 ident: CR82 article-title: Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance publication-title: Hepatology doi: 10.1002/hep.29762 contributor: fullname: Ziol – volume: 70 start-page: 3052 year: 2010 end-page: 3061 ident: CR101 article-title: 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-3690 contributor: fullname: Vincent – volume: 4 start-page: 779 year: 2016 end-page: 788 ident: CR1 article-title: Myeloma drug resistance induced by binding of myeloma B7–H1 (PD-L1) to PD-1 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-15-0296 contributor: fullname: Ishibashi – volume: 10 start-page: 200111 year: 2020 ident: CR102 article-title: Mechanisms of immune suppression by MDSC: the role of IL-10 as a key immunoregulatory cytokine publication-title: Open Biol doi: 10.1098/rsob.200111 contributor: fullname: Daoud – volume: 549 start-page: 106 year: 2017 end-page: 110 ident: CR23 article-title: Identification of CMTM6 and CMTM4 as PD-L1 protein regulators publication-title: Nature doi: 10.1038/nature23669 contributor: fullname: Mezzadra – volume: 3 start-page: 399 year: 2015 end-page: 411 ident: CR89 article-title: Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-14-0215 contributor: fullname: Winograd – volume: 107 start-page: 1563 year: 2016 end-page: 1571 ident: CR2 article-title: Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy publication-title: Cancer Sci doi: 10.1111/cas.13072 contributor: fullname: Zhang – volume: 70 start-page: 1015 year: 2021 end-page: 1029 ident: CR29 article-title: OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-020-02741-2 contributor: fullname: Pang – volume: 16 start-page: 220 year: 2014 end-page: 223 ident: CR51 article-title: Tackling gliomas with nanoformulated antineoplastic drugs: suitability of hyaluronic acid nanoparticles publication-title: Clin Transl Oncol doi: 10.1007/s12094-013-1114-1 contributor: fullname: Ganau – volume: 515 start-page: 558 year: 2014 end-page: 562 ident: CR14 article-title: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer publication-title: Nature doi: 10.1038/nature13904 contributor: fullname: Powles – volume: 13 start-page: 4429 year: 2007 end-page: 4434 ident: CR49 article-title: Triple-negative breast cancer: clinical features and patterns of recurrence publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-3045 contributor: fullname: Dent – volume: 373 start-page: 123 year: 2015 end-page: 135 ident: CR60 article-title: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1504627 contributor: fullname: Brahmer – volume: 553 start-page: 91 year: 2018 end-page: 95 ident: CR7 article-title: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance publication-title: Nature doi: 10.1038/nature25015 contributor: fullname: Zhang – volume: 17 start-page: 129 year: 2018 ident: CR35 article-title: Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors publication-title: Mol Cancer doi: 10.1186/s12943-018-0864-3 contributor: fullname: Yi – volume: 10 year: 2020 ident: CR71 article-title: Increased expression of SHMT2 is associated with poor prognosis and advanced pathological grade in oral squamous cell carcinoma publication-title: Front Oncol doi: 10.3389/fonc.2020.588530 contributor: fullname: Wu – volume: 6 start-page: 54 year: 2018 ident: CR47 article-title: CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors publication-title: Ann Transl Med doi: 10.21037/atm.2017.11.26 contributor: fullname: Bertucci – volume: 439 start-page: 682 year: 2006 end-page: 687 ident: CR6 article-title: Restoring function in exhausted CD8 T cells during chronic viral infection publication-title: Nature doi: 10.1038/nature04444 contributor: fullname: Barber – volume: 20 year: 2019 ident: CR25 article-title: CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers publication-title: Biochem Biophys Rep doi: 10.1016/j.bbrep.2019.100690 contributor: fullname: Gao – volume: 380 start-page: 2095 year: 2012 end-page: 2128 ident: CR72 article-title: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010 publication-title: Lancet doi: 10.1016/s0140-6736(12)61728-0 contributor: fullname: Lozano – volume: 9 start-page: 131 year: 2021 ident: CR48 article-title: The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer publication-title: Ann Transl Med doi: 10.21037/atm-20-7616 contributor: fullname: Tian – volume: 88 year: 2020 ident: CR63 article-title: CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2020.106864 contributor: fullname: Shang – volume: 7 start-page: 71198 year: 2016 end-page: 71210 ident: CR46 article-title: Prognostic value of PDL1 expression in pancreatic cancer publication-title: Oncotarget doi: 10.18632/oncotarget.11685 contributor: fullname: Birnbaum – volume: 549 start-page: 101 year: 2017 end-page: 105 ident: CR22 article-title: CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity publication-title: Nature doi: 10.1038/nature23643 contributor: fullname: Burr – volume: 120 start-page: 13330 year: 2019 end-page: 13341 ident: CR57 article-title: An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade publication-title: J Cell Biochem doi: 10.1002/jcb.28607 contributor: fullname: Zhao – volume: 72 start-page: 1088 year: 2020 end-page: 1096 ident: CR74 article-title: Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of caucasian patients with chronic hepatitis B publication-title: J Hepatol doi: 10.1016/j.jhep.2020.01.007 contributor: fullname: Papatheodoridis – volume: 99 start-page: 15 year: 2021 end-page: 22 ident: CR91 article-title: Role of PD-L1 expression during the progression of submucosal gastric cancer publication-title: Oncology doi: 10.1159/000509033 contributor: fullname: Ubukata – volume: 8 year: 2020 ident: CR27 article-title: CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients publication-title: PeerJ doi: 10.7717/peerj.9536 contributor: fullname: Li – volume: 372 start-page: 311 year: 2015 end-page: 319 ident: CR13 article-title: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1411087 contributor: fullname: Ansell – volume: 515 start-page: 568 year: 2014 end-page: 571 ident: CR90 article-title: PD-1 blockade induces responses by inhibiting adaptive immune resistance publication-title: Nature doi: 10.1038/nature13954 contributor: fullname: Tumeh – year: 2021 ident: CR95 article-title: CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer publication-title: J Immunother Cancer doi: 10.1136/jitc-2020-001638 contributor: fullname: Peng – volume: 9 start-page: 1773 year: 2015 end-page: 1782 ident: CR4 article-title: Frequent expression of PD-L1 on circulating breast cancer cells publication-title: Mol Oncol doi: 10.1016/j.molonc.2015.05.009 contributor: fullname: Mazel – volume: 9 start-page: 5023 year: 2016 end-page: 5039 ident: CR33 article-title: PD-L1 expression in human cancers and its association with clinical outcomes publication-title: Onco Targets Ther doi: 10.2147/OTT.S105862 contributor: fullname: Yu – volume: 78 start-page: 2332 year: 2018 end-page: 2342 ident: CR56 article-title: IRAK1 Augments cancer stemness and drug resistance via the AP-1/AKR1B10 signaling cascade in hepatocellular carcinoma publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-17-2445 contributor: fullname: Cheng – volume: 37 start-page: 691 year: 2018 end-page: 696 ident: CR79 article-title: Association between polymorphisms in CMTM family genes and hepatocellular carcinoma in Guangxi of China publication-title: DNA Cell Biol doi: 10.1089/dna.2018.4274 contributor: fullname: Tan – volume: 50 start-page: 398 year: 2020 end-page: 402 ident: CR93 article-title: Retrospective studies—utility and caveats publication-title: J R Coll Physicians Edinb doi: 10.4997/JRCPE.2020.409 contributor: fullname: Goyal – volume: 10 year: 2020 ident: CR106 article-title: Prognostic implications of pan-cancer CMTM6 expression and its relationship with the immune microenvironment publication-title: Front Oncol doi: 10.3389/fonc.2020.585961 contributor: fullname: Zhao – volume: 366 start-page: 2455 year: 2012 end-page: 2465 ident: CR12 article-title: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1200694 contributor: fullname: Brahmer – volume: 6 start-page: 41339 year: 2015 end-page: 41349 ident: CR85 article-title: A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma publication-title: Oncotarget doi: 10.18632/oncotarget.5463 contributor: fullname: Jiang – volume: 14 start-page: 847 year: 2015 end-page: 856 ident: CR37 article-title: PD-L1 expression as a predictive biomarker in cancer immunotherapy publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-14-0983 contributor: fullname: Kurzrock – volume: 12 year: 2017 ident: CR36 article-title: PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis publication-title: PLoS One doi: 10.1371/journal.pone.0182692 contributor: fullname: Gu – volume: 70 start-page: 417 year: 2021 end-page: 429 ident: CR80 article-title: Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-020-02691-9 contributor: fullname: Liu – volume: 389 start-page: 2492 year: 2017 end-page: 2502 ident: CR76 article-title: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial publication-title: Lancet doi: 10.1016/s0140-6736(17)31046-2 contributor: fullname: El-Khoueiry – volume: 2 year: 2019 ident: CR21 article-title: Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2019.2535 contributor: fullname: Prasad – year: 2020 ident: CR52 article-title: Recent advances in myeloid-derived suppressor cell biology publication-title: Front Med doi: 10.1007/s11684-020-0797-2 contributor: fullname: Daoud – volume: 32 start-page: 519 year: 2020 end-page: 531 ident: CR45 article-title: PD-L1 is induced on the hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 up-regulation by the anti-HBV drug entecavir publication-title: Int Immunol doi: 10.1093/intimm/dxaa018 contributor: fullname: Yamamoto – year: 2021 ident: CR30 article-title: CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-021-02931-6 contributor: fullname: Wu – volume: 8 start-page: 179 year: 2020 end-page: 191 ident: CR67 article-title: Targeting CMTM6 suppresses stem cell-like properties and enhances antitumor immunity in head and neck squamous cell carcinoma publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-19-0394 contributor: fullname: Chen – volume: 9 year: 2014 ident: CR5 article-title: PD-L1 expression is increased in a subset of basal type breast cancer cells publication-title: PLoS One doi: 10.1371/journal.pone.0088557 contributor: fullname: Antonia – volume: 41 start-page: 2217 year: 2011 end-page: 2228 ident: CR88 article-title: Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity publication-title: Eur J Immunol doi: 10.1002/eji.201041235 contributor: fullname: Sierro – volume: 29 start-page: 971 year: 2015 end-page: 992 ident: CR66 article-title: Molecular aspects of head and neck cancer therapy publication-title: Hematol Oncol Clin North Am doi: 10.1016/j.hoc.2015.07.003 contributor: fullname: Rocco – volume: 22 start-page: 5642 year: 2016 end-page: 5650 ident: CR19 article-title: Genomic approaches to understanding response and resistance to immunotherapy publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-0066 contributor: fullname: Van Allen – year: 2021 ident: CR68 article-title: CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma publication-title: Oral Surg Oral Med Oral Pathol Oral Radiol doi: 10.1016/j.oooo.2021.02.019 contributor: fullname: Zhang – volume: 147 start-page: 2003 year: 2021 end-page: 2011 ident: CR105 article-title: The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-021-03616-4 contributor: fullname: Ishihara – volume: 77 year: 2019 ident: CR38 article-title: Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2019.105999 contributor: fullname: Qian – volume: 10 start-page: 5439 year: 2017 end-page: 5443 ident: CR78 article-title: Clinical significance of CMTM4 expression in hepatocellular carcinoma publication-title: Onco Targets Ther doi: 10.2147/OTT.S149786 contributor: fullname: Bei – volume: 4 start-page: 65 year: 2016 ident: CR103 article-title: 5-Fluorouracil upregulates cell surface B7–H1 (PD-L1) expression in gastrointestinal cancers publication-title: J Immunother Cancer doi: 10.1186/s40425-016-0163-8 contributor: fullname: Van Der Kraak – volume: 136 start-page: E359 year: 2015 end-page: 386 ident: CR65 article-title: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 publication-title: Int J Cancer doi: 10.1002/ijc.29210 contributor: fullname: Ferlay – volume: 145 start-page: 1785 year: 2019 end-page: 1794 ident: CR100 article-title: PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-019-02942-y contributor: fullname: Ho – volume: 6 start-page: 178 year: 2022 end-page: 193 ident: CR31 article-title: Inhibition of CMTM4 sensitizes cholangiocarcinoma and hepatocellular carcinoma to T cell-mediated antitumor immunity through PD-L1 publication-title: Hepatol Commun doi: 10.1002/hep4.1682 contributor: fullname: Chui – year: 2021 ident: CR8 article-title: WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers publication-title: Gastric Cancer doi: 10.1007/s10120-021-01176-7 contributor: fullname: Jin – volume: 7 start-page: 235 year: 2018 end-page: 260 ident: CR73 article-title: Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition) publication-title: Liver Cancer doi: 10.1159/000488035 contributor: fullname: Zhou – volume: 373 start-page: 1803 year: 2015 end-page: 1813 ident: CR17 article-title: Nivolumab versus everolimus in advanced renal-cell carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1510665 contributor: fullname: Motzer – volume: 21 start-page: 702 year: 2019 end-page: 712 ident: CR39 article-title: Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives publication-title: Clin Transl Oncol doi: 10.1007/s12094-018-1975-4 contributor: fullname: Leucuta – volume: 17 start-page: 1598 year: 2020 end-page: 1609 ident: CR70 article-title: Overexpression of ATAD2 indicates poor prognosis in oral squamous cell carcinoma publication-title: Int J Med Sci doi: 10.7150/ijms.46809 contributor: fullname: Wang – volume: 372 start-page: 2509 year: 2015 end-page: 2520 ident: CR16 article-title: PD-1 blockade in tumors with mismatch-repair deficiency publication-title: N Engl J Med doi: 10.1056/NEJMoa1500596 contributor: fullname: Le – volume: 52 start-page: 149 year: 2020 end-page: 166 ident: CR41 article-title: Therapeutic co-targeting of WEE1 and ATM downregulates PD-L1 expression in pancreatic cancer publication-title: Cancer Res Treat doi: 10.4143/crt.2019.183 contributor: fullname: Jin – ident: CR32 – volume: 15 start-page: 971 year: 2009 end-page: 979 ident: CR75 article-title: Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-1608 contributor: fullname: Gao – volume: 11 start-page: 5365 year: 2021 end-page: 5386 ident: CR83 article-title: Turning cold tumors into hot tumors by improving T-cell infiltration publication-title: Theranostics doi: 10.7150/thno.58390 contributor: fullname: Sun – volume: 20 start-page: 82 year: 2019 ident: CR50 article-title: Targeted therapies for triple-negative breast cancer publication-title: Curr Treat Options Oncol doi: 10.1007/s11864-019-0682-x contributor: fullname: Lyons – year: 2019 ident: CR55 article-title: IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer publication-title: JCI Insight doi: 10.1172/jci.insight.130867 contributor: fullname: Li – volume: 373 start-page: 1627 year: 2015 end-page: 1639 ident: CR59 article-title: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1507643 contributor: fullname: Borghaei – year: 2021 ident: CR69 article-title: Overexpression of CD168 is related to poor prognosis in oral squamous cell carcinoma publication-title: Oral Dis doi: 10.1111/odi.13766 contributor: fullname: Zhu – volume: 9 start-page: 562 year: 2003 end-page: 567 ident: CR87 article-title: Blockade of B7–H1 improves myeloid dendritic cell-mediated antitumor immunity publication-title: Nat Med doi: 10.1038/nm863 contributor: fullname: Curiel – volume: 2 start-page: 361 year: 2014 end-page: 370 ident: CR3 article-title: PD-L1 expression in triple-negative breast cancer publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-13-0127 contributor: fullname: Mittendorf – volume: 74 start-page: 1215 year: 2019 end-page: 1226 ident: CR9 article-title: PD-L1 (B7–H1) competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy publication-title: Mol Cell doi: 10.1016/j.molcel.2019.04.005 contributor: fullname: Tu – year: 2021 ident: CR42 article-title: HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer publication-title: Oncogene doi: 10.1038/s41388-021-01689-6 contributor: fullname: Wei – volume: 40 start-page: 3655 year: 2021 end-page: 3664 ident: CR10 article-title: Antibody-based cancer therapy publication-title: Oncogene doi: 10.1038/s41388-021-01811-8 contributor: fullname: Rader – volume: 10 start-page: 1864909 year: 2020 ident: CR94 article-title: Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy publication-title: Oncoimmunology doi: 10.1080/2162402X.2020.1864909 contributor: fullname: Rimm – volume: 10 start-page: 168 year: 2019 ident: CR84 article-title: Cold tumors: a therapeutic challenge for immunotherapy publication-title: Front Immunol doi: 10.3389/fimmu.2019.00168 contributor: fullname: Bonaventura – volume: 21 start-page: 78 year: 2021 ident: CR92 article-title: Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer publication-title: Cancer Cell Int doi: 10.1186/s12935-020-01734-6 contributor: fullname: Wang – volume: 5 start-page: 334 year: 2021 end-page: 348 ident: CR26 article-title: CMTM6 stabilizes PD-L1 expression and is a new prognostic impact factor in hepatocellular carcinoma publication-title: Hepatol Commun doi: 10.1002/hep4.1643 contributor: fullname: Yugawa – volume: 19 start-page: 142 year: 2019 ident: CR99 article-title: Programmed death ligand-1 expression in stage II colon cancer—experiences from a nationwide populationbased cohort publication-title: BMC Cancer doi: 10.1186/s12885-019-5345-6 contributor: fullname: Eriksen – volume: 66 start-page: 1463 year: 2017 end-page: 1473 ident: CR98 article-title: Tumour CD274 (PD-L1) expression and T cells in colorectal cancer publication-title: Gut doi: 10.1136/gutjnl-2016-311421 contributor: fullname: Masugi – volume: 178 start-page: 17 year: 2019 end-page: 33 ident: CR34 article-title: Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-019-05371-0 contributor: fullname: Li – volume: 10 year: 2020 ident: CR53 article-title: Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine publication-title: Open Biol doi: 10.1098/rsob.200111 contributor: fullname: Daoud – volume: 10 start-page: 473 year: 2020 end-page: 490 ident: CR104 article-title: T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer publication-title: Am J Cancer Res contributor: fullname: Fu – year: 2021 ident: CR43 article-title: Epithelial to mesenchymal transition regulates surface PD-L1 via CMTM6 and CMTM7 induction in breast cancer publication-title: Cancers (Basel) doi: 10.3390/cancers13051165 contributor: fullname: Xiao – volume: 38 start-page: 193 year: 2019 end-page: 197 ident: CR77 article-title: Expression and clinical significance of CMTM6 in hepatocellular carcinoma publication-title: DNA Cell Biol doi: 10.1089/dna.2018.4513 contributor: fullname: Zhu – volume: 15 start-page: 55 year: 2016 ident: CR97 article-title: Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer publication-title: Mol Cancer doi: 10.1186/s12943-016-0539-x contributor: fullname: Li – volume: 366 start-page: 2443 year: 2012 end-page: 2454 ident: CR11 article-title: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1200690 contributor: fullname: Topalian – volume: 372 start-page: 2018 year: 2015 end-page: 2028 ident: CR15 article-title: Pembrolizumab for the treatment of non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1501824 contributor: fullname: Garon – volume: 35 start-page: 233 year: 2018 end-page: 243 ident: CR20 article-title: CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas publication-title: EBioMedicine doi: 10.1016/j.ebiom.2018.08.012 contributor: fullname: Guan – volume: 12 year: 2021 ident: CR28 article-title: CMTM6-deficient monocytes in ANCA-associated vasculitis fail to present the immune checkpoint PD-L1 publication-title: Front Immunol doi: 10.3389/fimmu.2021.673912 contributor: fullname: Zeisbrich – volume: 389 start-page: 255 year: 2017 end-page: 265 ident: CR61 article-title: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial publication-title: Lancet doi: 10.1016/s0140-6736(16)32517-x contributor: fullname: Rittmeyer – volume: 553 start-page: 91 year: 2018 ident: 2811_CR7 publication-title: Nature doi: 10.1038/nature25015 contributor: fullname: J Zhang – volume: 389 start-page: 2492 year: 2017 ident: 2811_CR76 publication-title: Lancet doi: 10.1016/s0140-6736(17)31046-2 contributor: fullname: AB El-Khoueiry – volume: 3 start-page: 399 year: 2015 ident: 2811_CR89 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-14-0215 contributor: fullname: R Winograd – volume: 375 start-page: 1823 year: 2016 ident: 2811_CR62 publication-title: N Engl J Med doi: 10.1056/NEJMoa1606774 contributor: fullname: M Reck – year: 2021 ident: 2811_CR69 publication-title: Oral Dis doi: 10.1111/odi.13766 contributor: fullname: SW Zhu – volume: 88 year: 2020 ident: 2811_CR63 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2020.106864 contributor: fullname: X Shang – volume: 20 start-page: 82 year: 2019 ident: 2811_CR50 publication-title: Curr Treat Options Oncol doi: 10.1007/s11864-019-0682-x contributor: fullname: TG Lyons – volume: 9 start-page: 1773 year: 2015 ident: 2811_CR4 publication-title: Mol Oncol doi: 10.1016/j.molonc.2015.05.009 contributor: fullname: M Mazel – volume: 8 year: 2019 ident: 2811_CR58 publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1629261 contributor: fullname: YW Koh – volume: 70 start-page: 1015 year: 2021 ident: 2811_CR29 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-020-02741-2 contributor: fullname: X Pang – volume: 21 start-page: 254 year: 2021 ident: 2811_CR44 publication-title: Oncol Lett doi: 10.3892/ol.2021.12516 contributor: fullname: J Wang – volume: 78 start-page: 2332 year: 2018 ident: 2811_CR56 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-17-2445 contributor: fullname: BY Cheng – volume: 12 year: 2021 ident: 2811_CR28 publication-title: Front Immunol doi: 10.3389/fimmu.2021.673912 contributor: fullname: M Zeisbrich – volume: 11 start-page: 5365 year: 2021 ident: 2811_CR83 publication-title: Theranostics doi: 10.7150/thno.58390 contributor: fullname: YT Liu – volume: 15 start-page: 55 year: 2016 ident: 2811_CR97 publication-title: Mol Cancer doi: 10.1186/s12943-016-0539-x contributor: fullname: Y Li – volume: 7 start-page: 71198 year: 2016 ident: 2811_CR46 publication-title: Oncotarget doi: 10.18632/oncotarget.11685 contributor: fullname: DJ Birnbaum – volume: 373 start-page: 123 year: 2015 ident: 2811_CR60 publication-title: N Engl J Med doi: 10.1056/NEJMoa1504627 contributor: fullname: J Brahmer – volume: 549 start-page: 106 year: 2017 ident: 2811_CR23 publication-title: Nature doi: 10.1038/nature23669 contributor: fullname: R Mezzadra – volume: 515 start-page: 558 year: 2014 ident: 2811_CR14 publication-title: Nature doi: 10.1038/nature13904 contributor: fullname: T Powles – year: 2019 ident: 2811_CR55 publication-title: JCI Insight doi: 10.1172/jci.insight.130867 contributor: fullname: Q Li – year: 2021 ident: 2811_CR30 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-021-02931-6 contributor: fullname: X Wu – volume: 10 start-page: 1864909 year: 2020 ident: 2811_CR94 publication-title: Oncoimmunology doi: 10.1080/2162402X.2020.1864909 contributor: fullname: S Martinez-Morilla – volume: 136 start-page: E359 year: 2015 ident: 2811_CR65 publication-title: Int J Cancer doi: 10.1002/ijc.29210 contributor: fullname: J Ferlay – volume: 66 start-page: 1463 year: 2017 ident: 2811_CR98 publication-title: Gut doi: 10.1136/gutjnl-2016-311421 contributor: fullname: Y Masugi – year: 2021 ident: 2811_CR43 publication-title: Cancers (Basel) doi: 10.3390/cancers13051165 contributor: fullname: M Xiao – volume: 10 start-page: 1370 year: 2019 ident: 2811_CR54 publication-title: ACS Med Chem Lett doi: 10.1021/acsmedchemlett.9b00423 contributor: fullname: RB Kargbo – volume: 20 year: 2019 ident: 2811_CR25 publication-title: Biochem Biophys Rep doi: 10.1016/j.bbrep.2019.100690 contributor: fullname: F Gao – volume: 14 start-page: 2084 year: 2019 ident: 2811_CR24 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2019.09.014 contributor: fullname: J Zugazagoitia – volume: 22 start-page: 5642 year: 2016 ident: 2811_CR19 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-0066 contributor: fullname: DA Braun – volume: 515 start-page: 568 year: 2014 ident: 2811_CR90 publication-title: Nature doi: 10.1038/nature13954 contributor: fullname: PC Tumeh – volume: 32 start-page: 519 year: 2020 ident: 2811_CR45 publication-title: Int Immunol doi: 10.1093/intimm/dxaa018 contributor: fullname: Y Yamamoto – volume: 17 start-page: 129 year: 2018 ident: 2811_CR35 publication-title: Mol Cancer doi: 10.1186/s12943-018-0864-3 contributor: fullname: M Yi – volume: 373 start-page: 1627 year: 2015 ident: 2811_CR59 publication-title: N Engl J Med doi: 10.1056/NEJMoa1507643 contributor: fullname: H Borghaei – volume: 372 start-page: 2509 year: 2015 ident: 2811_CR16 publication-title: N Engl J Med doi: 10.1056/NEJMoa1500596 contributor: fullname: DT Le – volume: 10 year: 2020 ident: 2811_CR53 publication-title: Open Biol doi: 10.1098/rsob.200111 contributor: fullname: MM Yaseen – year: 2021 ident: 2811_CR8 publication-title: Gastric Cancer doi: 10.1007/s10120-021-01176-7 contributor: fullname: MH Jin – volume: 14 start-page: 847 year: 2015 ident: 2811_CR37 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-14-0983 contributor: fullname: SP Patel – volume: 10 year: 2020 ident: 2811_CR106 publication-title: Front Oncol doi: 10.3389/fonc.2020.585961 contributor: fullname: Y Zhao – volume: 99 start-page: 15 year: 2021 ident: 2811_CR91 publication-title: Oncology doi: 10.1159/000509033 contributor: fullname: Y Ubukata – volume: 145 start-page: 1785 year: 2019 ident: 2811_CR100 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-019-02942-y contributor: fullname: HL Ho – volume: 41 start-page: 2217 year: 2011 ident: 2811_CR88 publication-title: Eur J Immunol doi: 10.1002/eji.201041235 contributor: fullname: SR Sierro – volume: 15 start-page: 971 year: 2009 ident: 2811_CR75 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-1608 contributor: fullname: Q Gao – volume: 374 start-page: 2542 year: 2016 ident: 2811_CR18 publication-title: N Engl J Med doi: 10.1056/NEJMoa1603702 contributor: fullname: PT Nghiem – volume: 9 year: 2014 ident: 2811_CR5 publication-title: PLoS One doi: 10.1371/journal.pone.0088557 contributor: fullname: H Soliman – volume: 366 start-page: 2455 year: 2012 ident: 2811_CR12 publication-title: N Engl J Med doi: 10.1056/NEJMoa1200694 contributor: fullname: JR Brahmer – volume: 10 start-page: 200111 year: 2020 ident: 2811_CR102 publication-title: Open Biol doi: 10.1098/rsob.200111 contributor: fullname: MM Yaseen – volume: 40 start-page: 3655 year: 2021 ident: 2811_CR10 publication-title: Oncogene doi: 10.1038/s41388-021-01811-8 contributor: fullname: RS Goydel – volume: 13 start-page: 4429 year: 2007 ident: 2811_CR49 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-3045 contributor: fullname: R Dent – volume: 70 start-page: 417 year: 2021 ident: 2811_CR80 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-020-02691-9 contributor: fullname: LL Liu – volume: 9 start-page: 5023 year: 2016 ident: 2811_CR33 publication-title: Onco Targets Ther doi: 10.2147/OTT.S105862 contributor: fullname: X Wang – year: 2021 ident: 2811_CR68 publication-title: Oral Surg Oral Med Oral Pathol Oral Radiol doi: 10.1016/j.oooo.2021.02.019 contributor: fullname: S Zhang – volume: 10 start-page: 473 year: 2020 ident: 2811_CR104 publication-title: Am J Cancer Res contributor: fullname: D Fu – volume: 4 start-page: 779 year: 2016 ident: 2811_CR1 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-15-0296 contributor: fullname: M Ishibashi – volume: 10 year: 2020 ident: 2811_CR71 publication-title: Front Oncol doi: 10.3389/fonc.2020.588530 contributor: fullname: ZZ Wu – volume: 49 start-page: 2233 year: 2013 ident: 2811_CR96 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2013.02.015 contributor: fullname: RA Droeser – volume: 10 start-page: 5439 year: 2017 ident: 2811_CR78 publication-title: Onco Targets Ther doi: 10.2147/OTT.S149786 contributor: fullname: C Bei – volume: 70 start-page: 3052 year: 2010 ident: 2811_CR101 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-3690 contributor: fullname: J Vincent – volume: 52 start-page: 149 year: 2020 ident: 2811_CR41 publication-title: Cancer Res Treat doi: 10.4143/crt.2019.183 contributor: fullname: MH Jin – volume: 64 start-page: 1140 year: 2004 ident: 2811_CR86 publication-title: Cancer Res doi: 10.1158/0008-5472.can-03-3259 contributor: fullname: C Blank – volume: 178 start-page: 17 year: 2019 ident: 2811_CR34 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-019-05371-0 contributor: fullname: W Huang – volume: 19 start-page: 142 year: 2019 ident: 2811_CR99 publication-title: BMC Cancer doi: 10.1186/s12885-019-5345-6 contributor: fullname: AC Eriksen – volume: 10 start-page: 168 year: 2019 ident: 2811_CR84 publication-title: Front Immunol doi: 10.3389/fimmu.2019.00168 contributor: fullname: P Bonaventura – volume: 8 start-page: 179 year: 2020 ident: 2811_CR67 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-19-0394 contributor: fullname: L Chen – volume: 77 year: 2019 ident: 2811_CR38 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2019.105999 contributor: fullname: M Xie – volume: 16 start-page: 220 year: 2014 ident: 2811_CR51 publication-title: Clin Transl Oncol doi: 10.1007/s12094-013-1114-1 contributor: fullname: M Ganau – volume: 6 start-page: 178 year: 2022 ident: 2811_CR31 publication-title: Hepatol Commun doi: 10.1002/hep4.1682 contributor: fullname: NN Chui – volume: 83 year: 2020 ident: 2811_CR64 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2020.106478 contributor: fullname: H Wang – volume: 17 start-page: 1598 year: 2020 ident: 2811_CR70 publication-title: Int J Med Sci doi: 10.7150/ijms.46809 contributor: fullname: XL Wang – volume: 2 start-page: 361 year: 2014 ident: 2811_CR3 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-13-0127 contributor: fullname: EA Mittendorf – year: 2020 ident: 2811_CR52 publication-title: Front Med doi: 10.1007/s11684-020-0797-2 contributor: fullname: MM Yaseen – volume: 9 start-page: 131 year: 2021 ident: 2811_CR48 publication-title: Ann Transl Med doi: 10.21037/atm-20-7616 contributor: fullname: Y Tian – volume: 5 start-page: 334 year: 2021 ident: 2811_CR26 publication-title: Hepatol Commun doi: 10.1002/hep4.1643 contributor: fullname: K Yugawa – volume: 42 start-page: 1459 year: 2019 ident: 2811_CR40 publication-title: Oncol Rep doi: 10.3892/or.2019.7244 contributor: fullname: E Tanaka – volume: 9 start-page: 562 year: 2003 ident: 2811_CR87 publication-title: Nat Med doi: 10.1038/nm863 contributor: fullname: TJ Curiel – volume: 373 start-page: 1803 year: 2015 ident: 2811_CR17 publication-title: N Engl J Med doi: 10.1056/NEJMoa1510665 contributor: fullname: RJ Motzer – volume: 6 start-page: 54 year: 2018 ident: 2811_CR47 publication-title: Ann Transl Med doi: 10.21037/atm.2017.11.26 contributor: fullname: E Mamessier – volume: 372 start-page: 311 year: 2015 ident: 2811_CR13 publication-title: N Engl J Med doi: 10.1056/NEJMoa1411087 contributor: fullname: SM Ansell – volume: 29 start-page: 971 year: 2015 ident: 2811_CR66 publication-title: Hematol Oncol Clin North Am doi: 10.1016/j.hoc.2015.07.003 contributor: fullname: SV Puram – volume: 72 start-page: 1088 year: 2020 ident: 2811_CR74 publication-title: J Hepatol doi: 10.1016/j.jhep.2020.01.007 contributor: fullname: GV Papatheodoridis – volume: 372 start-page: 2018 year: 2015 ident: 2811_CR15 publication-title: N Engl J Med doi: 10.1056/NEJMoa1501824 contributor: fullname: EB Garon – volume: 21 start-page: 78 year: 2021 ident: 2811_CR92 publication-title: Cancer Cell Int doi: 10.1186/s12935-020-01734-6 contributor: fullname: C Zhang – volume: 439 start-page: 682 year: 2006 ident: 2811_CR6 publication-title: Nature doi: 10.1038/nature04444 contributor: fullname: DL Barber – volume: 549 start-page: 101 year: 2017 ident: 2811_CR22 publication-title: Nature doi: 10.1038/nature23643 contributor: fullname: ML Burr – volume: 6 start-page: 41339 year: 2015 ident: 2811_CR85 publication-title: Oncotarget doi: 10.18632/oncotarget.5463 contributor: fullname: SS Jiang – ident: 2811_CR32 doi: 10.1007/s00262-022-03171-y – volume: 12 year: 2017 ident: 2811_CR36 publication-title: PLoS One doi: 10.1371/journal.pone.0182692 contributor: fullname: L Gu – volume: 4 start-page: 65 year: 2016 ident: 2811_CR103 publication-title: J Immunother Cancer doi: 10.1186/s40425-016-0163-8 contributor: fullname: L Van Der Kraak – volume: 147 start-page: 2003 year: 2021 ident: 2811_CR105 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-021-03616-4 contributor: fullname: S Ishihara – volume: 120 start-page: 13330 year: 2019 ident: 2811_CR57 publication-title: J Cell Biochem doi: 10.1002/jcb.28607 contributor: fullname: W Zhao – volume: 389 start-page: 255 year: 2017 ident: 2811_CR61 publication-title: Lancet doi: 10.1016/s0140-6736(16)32517-x contributor: fullname: A Rittmeyer – volume: 50 start-page: 398 year: 2020 ident: 2811_CR93 publication-title: J R Coll Physicians Edinb doi: 10.4997/JRCPE.2020.409 contributor: fullname: K Talari – volume: 380 start-page: 2095 year: 2012 ident: 2811_CR72 publication-title: Lancet doi: 10.1016/s0140-6736(12)61728-0 contributor: fullname: R Lozano – volume: 2 year: 2019 ident: 2811_CR21 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2019.2535 contributor: fullname: A Haslam – year: 2021 ident: 2811_CR42 publication-title: Oncogene doi: 10.1038/s41388-021-01689-6 contributor: fullname: Y Liu – volume: 7 start-page: 235 year: 2018 ident: 2811_CR73 publication-title: Liver Cancer doi: 10.1159/000488035 contributor: fullname: J Zhou – year: 2021 ident: 2811_CR95 publication-title: J Immunother Cancer doi: 10.1136/jitc-2020-001638 contributor: fullname: QH Peng – volume: 37 start-page: 691 year: 2018 ident: 2811_CR79 publication-title: DNA Cell Biol doi: 10.1089/dna.2018.4274 contributor: fullname: C Bei – volume: 8 year: 2020 ident: 2811_CR27 publication-title: PeerJ doi: 10.7717/peerj.9536 contributor: fullname: X Li – volume: 38 start-page: 193 year: 2019 ident: 2811_CR77 publication-title: DNA Cell Biol doi: 10.1089/dna.2018.4513 contributor: fullname: X Zhu – volume: 107 start-page: 1563 year: 2016 ident: 2811_CR2 publication-title: Cancer Sci doi: 10.1111/cas.13072 contributor: fullname: P Zhang – volume: 366 start-page: 2443 year: 2012 ident: 2811_CR11 publication-title: N Engl J Med doi: 10.1056/NEJMoa1200690 contributor: fullname: SL Topalian – volume: 67 start-page: 727 year: 2017 ident: 2811_CR81 publication-title: J Hepatol doi: 10.1016/j.jhep.2017.05.014 contributor: fullname: J Calderaro – volume: 35 start-page: 233 year: 2018 ident: 2811_CR20 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2018.08.012 contributor: fullname: X Guan – volume: 21 start-page: 702 year: 2019 ident: 2811_CR39 publication-title: Clin Transl Oncol doi: 10.1007/s12094-018-1975-4 contributor: fullname: T Mocan – volume: 74 start-page: 1215 year: 2019 ident: 2811_CR9 publication-title: Mol Cell doi: 10.1016/j.molcel.2019.04.005 contributor: fullname: X Tu – volume: 68 start-page: 103 year: 2018 ident: 2811_CR82 publication-title: Hepatology doi: 10.1002/hep.29762 contributor: fullname: M Ziol |
| SSID | ssj0055611 |
| Score | 2.3368552 |
| SecondaryResourceType | review_article |
| Snippet | The recent discovery of CMTM6 and to a lesser extent CMTM4, two members of the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family,... |
| SourceID | proquest crossref pubmed springer |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1478 |
| SubjectTerms | Medicine Medicine & Public Health Oncology Review Article |
| Title | The clinical and prognostic significance of CMTM6/PD-L1 in oncology |
| URI | https://link.springer.com/article/10.1007/s12094-022-02811-0 https://www.ncbi.nlm.nih.gov/pubmed/35278198 https://search.proquest.com/docview/2638748159 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8NAEB5sC-LF96M-ygreNDXJbrLZY1tbi5rioYV6CvtIQIREbHvQX-9uHhapCL3lkAf5ZjIzm5nvW4ArIpNAUhZYgceFRZTy9ZGPLcExd6iigSSGnByO_OGEPEy96ZLHnQ-7Vx3JPFAvuW6ubVRs9dpJp0TzX68GDUM89erQ6Ny_PParAGw2fHRKfszfV_7OQSuF5UpTNM81gx0YV4ydYsTkrb2Yi7b8WhVwXOc1dmG7rD1Rp3CWPdiI033YDMvu-gH0tM-giiqJeKqQmd5KMyPljMyghxkrMl6CsgT1wnHo3z7fWU8Oek1Rluby15-HMBn0x72hVW6yYElM6NzCMWfct2nsBw5OiENporyEM-Ypnwvucio0xjHmel0iKFV6QSIV82LuYyw5ZvgI6mmWxieAPMIVSwgTUtqESBYkUugCkXElhCuF04TrCvbovdDSiJaqyQaXSOMS5bhEdhMuK8tE2uVNH4OncbaYRa6OGdSIzLAmHBcm-7mfriepLnKCJtxU-EflVzn752Gn651-BltubkIzCHgO9fnHIr7QxclctLQzDrrdUat0yhbUJm7nGxcJ25Q |
| link.rule.ids | 315,783,787,27938,27939,41095,41537,42164,42606,52125,52248 |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT8MwDLZgk4AL78d4BokbdKxN2jRHNB6DrYjDJo1TlEcrIaQWse4Av56ka5lgCGm3Hvq0XftzbH8BOCMqCRVloRP6QjpE68AcBdiRAguXahoqYoeTo8egMyAPQ39YDoWNqm73qiRZeOrpsJvXsjS2JnkyMdEu7C1CnXgG7tegfnX33L2pPLDd8dEtB2T-vvJnEJpBljNV0SLY3K7BoHrNSY_Ja3Ocy6b6_MXgOO93rMNqiT7R1cRcNmAhTjdhKSrr61vQNlaDqmFJJFKNbP9WmlkyZ2RbPWxjkbUTlCWoHfWj4PLp2um56CVFWVoQYH9sw-D2pt_uOOU2C47ChOYOjgUTQYvGQejihLiUJtpPBGO-DoQUnqDSoKAYC5OZSEq1SUmUZn4sAoyVwAzvQC3N0ngPkE-EZglhUqkWIYqFiZIGIjKhpfSUdBtwXsmdv03YNPiUN9nKhRu58EIuvNWA00o13Bi9rWSINM7GI-4Zr0EtzQxrwO5EZ9_3M4iSGpgTNuCikj8v_8vRPw_bn-_0E1ju9KMe790_dg9gxSvUadsCD6GWv4_jIwNVcnlcWuYXBjfdAw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB6VRUJc2kILTR_USL3RsEnsxPFxtcuW1yIOIMHJGtuJhJAc1M0eyq_HzqPbFlQJccshz5mx53Pmm88A35guc81FHuYpqpAZk7mjjIYKKcbc8Fwz35w8O8sOL9nxVXr1Rxd_w3bvS5JtT4NXabL18M6Uw2XjWxJ5SVu3kHL50f_kW4FVFju4MIDV0Y_rk4N-Nva7P8Zds8zTV_6dkB6hzEcV0ibxTN8A9q_c8k1u9xe12tf3_6g5vuSb3sLrDpWSURtGG_CqsJuwNuvq7u9g7KKJ9E2UBK0hntdlKy_yTDwFxBOOfPyQqiTj2cUsG55PwtOY3FhS2UYY-9d7uJweXIwPw277hVBTxuuQFigwi3iR5TEtWcx5adIShUhNhgoT5Mqho4KiW7Eozo1bqmgj0gIzSjVSQbdgYCtbfACSMjSiZEJpHTGmRV5q5aCjQKNUolUcwF7vA3nXqmzIpZ6yt4t0dpGNXWQUwG7vJukGg69woC2qxVwmbjbhXn5GBLDd-u_3_RzS5A7-5AF8730hu_E6_8_DPj7v9K-wdj6ZytOjs5NPsJ403vRswc8wqH8uii8OwdRqpwvSByCP5ec |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+clinical+and+prognostic+significance+of+CMTM6%2FPD-L1+in+oncology&rft.jtitle=Clinical+%26+translational+oncology&rft.au=Yaseen%2C+Mahmoud+Mohammad&rft.au=Abuharfeil%2C+Nizar+Mohammad&rft.au=Darmani%2C+Homa&rft.date=2022-08-01&rft.eissn=1699-3055&rft_id=info:doi/10.1007%2Fs12094-022-02811-0&rft_id=info%3Apmid%2F35278198&rft.externalDocID=35278198 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1699-3055&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1699-3055&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1699-3055&client=summon |